| Not Yet Recruiting | Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leu NCT07439211 | Jacqueline Garcia, MD | Phase 1 |
| Recruiting | Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Bla NCT06643962 | Affiliated Hospital of Nantong University | N/A |
| Recruiting | Breath Analysis for the Detection of Invasive Fungal Infections NCT06537726 | University of Zurich | — |
| Not Yet Recruiting | ELN 2022 in MENAFC ( Middle Eastern or North Coast of Africa ) Patients With Newly AML NCT06512610 | Centre Hospitalier Universitaire de Nice | — |
| Recruiting | A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrom NCT06501196 | BlossomHill Therapeutics | Phase 1 |
| Recruiting | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT06001788 | Kura Oncology, Inc. | Phase 1 |
| Recruiting | CIML NK Cells With Venetoclax for AML NCT06152809 | Dana-Farber Cancer Institute | Phase 1 |
| Recruiting | Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation NCT06138587 | Dana-Farber Cancer Institute | Phase 1 |
| Recruiting | Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia NCT05458258 | University of Chicago | — |
| Completed | CD155 Expression in Acute Myeloid Leukemia NCT06369662 | Assiut University | — |
| Recruiting | Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase NCT05143840 | Augusta University | Phase 2 |
| Completed | Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation NCT05282459 | Tian Yi Zhang | Phase 1 / Phase 2 |
| Terminated | A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidi NCT04748848 | Celgene | Phase 1 |
| Terminated | Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia NCT04789655 | Celgene | Phase 1 |
| Completed | A Multicentre, Retrospective Study to Evaluate the Outcome of HSCT Mismatch Unrelated Donors NCT04598789 | Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna | — |
| Withdrawn | Endogenous Retroviruses in Acute Myeloid Leukemia NCT04406207 | Hospices Civils de Lyon | — |
| Terminated | Natural Killer Cell (CYNK-001) Infusions in Adults with AML NCT04310592 | Celularity Incorporated | Phase 1 |
| Unknown | Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia NCT04272125 | Chongqing Precision Biotech Co., Ltd | Phase 1 / Phase 2 |
| Completed | Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease NCT04039100 | Rigshospitalet, Denmark | N/A |
| Unknown | CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia NCT04265963 | Chongqing Precision Biotech Co., Ltd | Phase 1 / Phase 2 |
| Unknown | Efficacy of FLAG Regimen for the Treatment of Patients With AML NCT03600558 | Tianjin Medical University General Hospital | — |
| Unknown | A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML NCT03417427 | Xuejie Jiang | Phase 2 |
| Completed | Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS NCT03066648 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG NCT02916979 | Dartmouth-Hitchcock Medical Center | Phase 1 |
| Terminated | Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodyspl NCT02370888 | University of Florida | Phase 1 |
| Unknown | High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML NCT03080922 | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Phase 1 / Phase 2 |
| Completed | An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Lat NCT02577406 | Celgene | Phase 3 |
| Completed | A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia NCT02538965 | Celgene | Phase 2 |
| Unknown | Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies NCT02333838 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Completed | Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phas NCT01511289 | Il-Yang Pharm. Co., Ltd. | Phase 3 |
| Completed | Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodyspl NCT01392989 | Everett Meyer | Phase 2 |
| Completed | Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia NCT01050036 | Asan Medical Center | N/A |
| Completed | Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI NCT01602952 | Il-Yang Pharm. Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias NCT01144793 | Stanford University | — |
| Completed | Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia NCT00611247 | Bruno C. Medeiros | Phase 2 |
| Terminated | Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML NCT00568633 | Stanford University | Phase 3 |
| Completed | Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia NCT00512083 | Antisoma Research | Phase 2 |
| Terminated | T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation NCT00306332 | Radboud University Medical Center | Phase 3 |
| Completed | A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myel NCT00233909 | Kanisa Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute M NCT00129168 | Kanisa Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes NCT00451997 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Analyses of Human Samples Collected in Clinical Trials NCT00339664 | National Cancer Institute (NCI) | — |
| Completed | Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelody NCT00065143 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation NCT00030186 | Cephalon | Phase 2 |
| Completed | Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS NCT00025662 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |